Cushing's Disease Clinical Trial
Official title:
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease
The USP8 gene and its downstream target, epidermal growth factor receptor (EGFR), is a potential therapeutic target of Cushing disease. The EGFR inhibitor, Gefitinib, has been shown to reduce the production of ACTH both in vitro and in vivo, especially in USP8-mutated corticotrophin adenomas. The investigators hypothesize that Gefitinib will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with USP8-mutated Cushing's disease. Gefitinib is an FDA approved drug used to treat non-small cell lung cancer. However, in this study, the drug will be used to treat corticotrophin adenoma.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00881283 -
Long-term Cardiovascular Risk in Cured Cushing's Patients
|
||
| Completed |
NCT02568982 -
Cushing's Disease Complications
|
||
| Completed |
NCT02697734 -
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
|
Phase 3 | |
| Completed |
NCT01374906 -
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
|
Phase 3 | |
| Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
| Not yet recruiting |
NCT02603653 -
Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease
|
N/A | |
| Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
| Recruiting |
NCT00845351 -
Preoperative Bexarotene Treatment for Cushing's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT00889525 -
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
|
Phase 3 | |
| Completed |
NCT02060383 -
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
|
Phase 4 | |
| Recruiting |
NCT04339751 -
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
|
Phase 2 | |
| Not yet recruiting |
NCT04569591 -
Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease
|
N/A | |
| Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
| Active, not recruiting |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
| Completed |
NCT00434148 -
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
|
Phase 3 | |
| Completed |
NCT03346954 -
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
|
N/A | |
| Withdrawn |
NCT01925092 -
Mifepristone in Children With Refractory Cushing's Disease
|
Phase 3 | |
| Completed |
NCT01582061 -
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
|
Phase 3 | |
| Recruiting |
NCT03708900 -
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease
|
Phase 2 | |
| Terminated |
NCT00612066 -
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
|
Phase 2 |